NeurogesX Inc.

Anthony A. DiTonno joined us as Chief Operating Officer in April 2003, and has served as our President and Chief Executive Officer since August 2003. From October 2000 to November 2002, Mr. DiTonno served as Executive Vice President of Sales and Marketing for Enteric Medical Technologies, Inc., a medical device company. From 1997 to 2000, Mr. DiTonno served as Chief Executive Officer of LifeSleep Systems, Inc., a medical device company. From 1989 to 1997, Mr. DiTonno held various positions at Oclassen Pharmaceuticals, Inc., a pharmaceutical company, most recently as its Vice President and General Manager. Mr. DiTonno received a B.S. in business administration from St. Joseph’s University and an M.B.A. from Drexel University.

Jeffrey K. Tobias, M.D. has served as our Chief Medical Officer since November 2005. Dr. Tobias brings more than 18 years experience in domestic and international clinical drug development, regulatory submissions and strategic planning. From September 1996 to November 2005, Dr. Tobias served as owner and principal of the Aquila Consulting Group, a professional consulting firm specializing in clinical development, and strategic planning for U.S. and international biotechnology and pharmaceutical companies. From June 1995 to September 1996, Dr. Tobias served as Director, New Product Discovery at Alza Corporation, a drug delivery solutions company. Previous to these activities, Dr. Tobias was director, clinical development at Chiron Corporation, and director, clinical research at Xoma Corporation. Dr. Tobias received board-certification in both Internal Medicine and Pulmonary Medicine and completed training in Critical Care Medicine at the University of California, Los Angeles. He received his bachelor's degree and medical degree with honors from the University of Illinois.

Stephen F. Ghiglieri has served as our Chief Financial Officer since October 2003. From December 2002 to October 2003, Mr. Ghiglieri served as Chief Financial Officer of Hansen Medical, Inc., a medical device company. From March 2000 to April 2002, Mr. Ghiglieri served as Executive Vice President, Chief Financial Officer and Corporate Secretary of Avolent, Inc., a software company. From July 1999 to 2000, Mr. Ghiglieri served as Vice President, Finance, Chief Financial Officer and Corporate Secretary of Andromedia, Inc., a software company. From 1994 to 1999, Mr. Ghiglieri served as Vice President, Finance and Administration, Chief Financial Officer and Corporate Secretary of Oacis Healthcare Systems, Inc., a healthcare technology company. From 1992 to 1994, Mr. Ghiglieri served as Controller of Oclassen Pharmaceuticals, Inc., a pharmaceutical company. From 1984 to 1992, Mr. Ghiglieri served as an audit manager of PricewaterhouseCoopers, LLP. Mr. Ghiglieri received a B.A. in business administration from California State University, Hayward. Mr. Ghiglieri is also a Certified Public Accountant.

Keith R. Bley, Ph.D. has served as our Senior Vice President, Nonclinical Research and Development since August 2001 and prior to that served as our Vice President, Nonclinical Research and Development since June 2000. From 1991 to 2000, Dr. Bley held various positions at Roche Bioscience and Syntex (later acquired by Roche Bioscience), most recently as a Research Manager in the analgesia department. Dr. Bley received an M.A. in philosophy from Columbia University and a Ph.D. in cellular and molecular physiology from Yale University.

Allan Basbaum grew up in Montreal,Canada, where he learned French as a second language and did undergraduate studies at McGill University. After training at the University of Pennsylvania and University College London he accepted a position at UCSF. He is presently Professor and Chair of the Department of Anatomy, where he teaches neuroanatomy to Medical Students and runs a neuroscience research laboratory that addresses the mechanisms that underlie the development of persistent pain conditions. He is on the Scientific Advisory Board of Cognetix Corp., Analgesics, and the Restless Legs Syndrome Foundation. Allan was appointed to the French American and International board in 1988, and served as President until 2004. Since his daughter Katherine began school when French American and International was located on Grove Street, and was called FABS, the move to the Oak Street Campus was the second major move since Allan's affiliation with the school began. Among the accomplishments of the Board during his Presidency are, of course, the move to Oak Street, the dramatic and successful growth of the high school and the high recognition now given to the French American-CAIS international (bilingual) models of education in the local, national and international communities.

David Julius is currently a Professor in the Department of Cellular & Molecular Pharmacology at the University of California, San Francisco. He is interested in the molecular biology of sensory transduction and neurotransmitter action in the mammalian nervous system. One of his goals is to understand the molecular basis of somatosensation - the process whereby we experience touch and temperature - with an emphasis on identifying molecules that detect noxious (pain-producing) stimuli. He is also interested in understanding how somatosensation is altered in response to tissue or nerve injury. David received his Ph.D. in Biochemistry from the University of California, Berkeley, and his bachelor's degree from the Massachusetts Institute of Technology.

Dr. Katz is internationally known expert in pain management and analgesic clinical trials. His contributions to research include numerous clinical trials of treatments for pain, involving pharmaceuticals, non-pharmaceutical analgesics and devices, with a particular focus on opioids and risk management. From 2000-2004 Dr. Katz served as Chair of the Advisory Committee, Anesthesia, Critical Care, and Addiction Products Division, at the FDA. In 2006, Analgesic Research was founded by the addition of a number of other top experts in different disciplines, all focusing on development of analgesics.

Jean-Jacques Bienaimé has served as a member of our board of directors since February 2004. Since May 2005, Mr. Bienaimé has served as Chief Executive Officer and director of BioMarin Pharmaceutical Inc., a publicly-held biopharmaceutical company. From November 2002 to April 2005, Mr. Bienaimé served as the Chairman, Chief Executive Officer and President of Genencor International, a biotechnology company acquired by Danisco A/S. From June 1998 to October 2002, Mr. Bienaimé was Chief Executive Officer and President of SangStat Medical, a biotechnology company. From October 1992 to May 1998, Mr. Bienaimé held various management positions, most recently as Senior Vice President of Corporate Marketing and Business Development, and Vice President and General Manager of the advanced therapeutic and oncology division of Rhône-Poulenc Rorer Pharmaceuticals (now The Sanofi-Aventis Group), a pharmaceutical company. Mr. Bienaimé received a B.S. in economics from the Ecole Supérieure de Commerce de Paris and an M.B.A. from the Wharton School at the University of Pennsylvania.

Bruce A. Peacock has been a director and served as chairman of the Company's Audit Committee since August 2007. Since April 2008, Mr Peacock has served as President and CEO of Alba Therapeutics, a privately held biopharmaceutical company. In addition, Mr Peacock has been a Venture Partner with SV Life Sciences Advisors, LLC since May 2006. Mr. Peacock has extensive senior management experience in multiple biotechnology, medical device/pharmaceutical/and healthcare services companies. He was most recently CEO of The Little Clinic, a medical care services company, and prior to that served as President and CEO of Adolor Corporation, a publicly traded biopharmaceutical company, and as President and Chief Executive Officer and Director of Orthovita, Inc, an orthopaedic products company. He has also held senior management positions at Cephalon, Inc., where he was Executive Vice President, Chief Operating Officer and a Director, and at Centocor, Inc., where he was Senior Vice President and Chief Financial Officer.

Daniel Turner is a successful entrepreneur in the IT industry with over 15 years experience providing network support. He has over 6 years full-time experience operating and managing PC Commuters and DotCom Director, Inc. providing network consulting, Web application development and providing Internet access as an ISP to the legal community in Los Angeles. He is recognized by his clients as a hands-on, proactive troubleshooter who rapidly identifies technical challenges, formulates strategic plans, and initiates appropriate changes in challenging and diverse environments. His management style effectively motivates others and helps raise the level of achievement of individual and organizations. Mr. Turner earned a B.S. in Electrical Engineering from California State University, Northridge.

Mr. Bienaimé joined BioMarin in May 2005 as chief executive officer and member of the board of directors, bringing with him over 25 years of experience in the biotechnology and pharmaceutical industries. Under his leadership, the market capitalization of BioMarin went from around $450 million in May 2005 to over $3.5 billion in May 2008. BioMarin 2008 revenues around $300 million and is a fully integrated biopharmaceutical company with over 700 employees. From November 2002 to April 2005, Mr. Bienaimé served as chairman, chief executive officer, and president of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Under his leadership, Genencor's revenues increased substantially to over $400 million and shareholder value increased dramatically, culminating in the sale of the company to Danisco in the spring of 2005 for an enterprise value of over $1.2 billion. From 1998 to late 2002, Mr. Bienaimé served as chairman, chief executive officer and president of Sangstat Medical Corporation, an immunology-focused biotechnology company that he guided to profitability prior to its acquisition by Genzyme Corporation. From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), culminating in the position of senior vice president of worldwide marketing and business development responsible for, among other things, the launch of Lovenox® (for the prevention of pulmonary embolism and treatment of unstable angina) in the United States and Taxotere® (for breast and lung cancer) worldwide. Earlier in his career, he worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. Mr. Bienaimé is chairman of the board of directors of NeurogesX, Inc., a member of the board of directors of Ensemble Discovery Corporation, and is a member of the advisory board of Bellevue Asset Management's BioVentures II fund. He received an M.B.A from the Wharton School at the University of Pennsylvania and an undergraduate degree in economics from the Ecole Superieure de Commerce de Paris.

Neil M. Kurtz, M.D. has served as a member of our Board of Directors since January 2006. Since August 2008, Dr. Kurtz has served as President and Chief Executive Officer of Golden Living, a healthcare services company. From April 2002 to August 2008, Dr. Kurtz has served as President and Chief Executive Officer and Director of TorreyPines Therapeutics, Inc., a biopharmaceutical company. From September 1999 to April 2002, Dr. Kurtz was President of World-Wide Clinical Trials, a healthcare solutions company. Dr. Kurtz received a B.A. in psychology from New York University and an M.D. from the Medical College of Wisconsin.